PDCD1 and neoplasm: The contribution of SHP2 to PD-1 signaling in T cells was most directly studied in a T cell confined SHP2 knockout (KO) mouse study that found no effect on controlling tumor growth or on the efficacy of PD-1 antibodies, likely due to the impact on SHP2’s role in both T cell activating and inhibitory pathways.